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INTRODUCTION
Elevated intraocular pressure (IOP) is a major risk 
factor for the development and progression of 
glaucoma.[1–3] Therefore, IOP measurements provide 
important information to clinicians about glaucoma 
diagnosis, assessing the possibility of progression, and 
monitoring the clinical response to therapy.
It is well known that intraocular pressure is not a 
fixed value but fluctuates over time. Although there 
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Abstract
Elevated intraocular pressure (IOP) is a major risk factor for the development and progression of glaucoma. 
Previous prospective, randomized, long‑term studies have demonstrated the strength of IOP reduction in 
slowing the progression of disease. It is well known that IOP is not a fixed value but fluctuates considerably 
over time. Although there have been some studies on IOP fluctuation and the progression of glaucoma, 
whether IOP fluctuation is an independent risk factor for glaucomatous damage and disease progression 
remains controversial. In this article, we reviewed the definition of IOP fluctuation, and both the evidence 
and the speculation for and against the effect of IOP fluctuation on glaucoma progression. Although 
conclusions seem to vary from study to study, we considered that different studies examined different 
groups of patients, at different stages of disease, and at different IOP levels. Our conclusion is that these 
apparently disparate results are not conflicting, but rather can be viewed as complementary. In clinical care, 
we recommend the consideration of IOP “modulation” rather than just IOP “reduction” when glaucoma 
patients are treated. Quality‑based IOP control may be more effective than quantity‑based IOP reduction 
to prevent or retard disease progression.
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have been a number of studies on IOP fluctuation and 
the progression of glaucoma, whether IOP fluctuation 
is an independent risk factor for glaucomatous damage 
and disease progression remains controversial. Here, we 
will review the definition of IOP fluctuation, the evidence 
for and against the effect of IOP fluctuation on glaucoma 
progression, and what we should consider when we 
manage glaucoma patients in clinical practice.
IOP fluctuation can be categorized according to the 
period of time over which the IOP is monitored.
1. Instantaneous IOP fluctuation is defined as the IOP 
variation that occurs over a very short time period 
of time (seconds), and is caused by saccades, blinks, 
eye rubbing, etc.;
2. Diurnal‑nocturnal IOP fluctuation, or nyctohemeral 
fluctuation, refers to IOP variation that occurs over 
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the course of a day. The diurnal IOP changes may 
be partly explained by bodily postural changes 
associated with blood pressure and episcleral 
venous pressure changes, diurnal fluctuations in 
cortisol levels, variations in aqueous production, 
environmental light and dark cycles, and perhaps 
seasonal influences.[4–9] This type of IOP fluctuation 
is also often referred to as central, or humoral IOP 
fluctuation;
3. Short‑term IOP fluctuation is defined as the IOP 
fluctuation that occurs over days to weeks; and
4. Long‑term IOP fluctuation is defined as that which 
occurs over months to years. A measure of long‑term 
fluctuation can be obtained from repeated IOP 
measurements that occur during serial office visits.
There have been a number of investigations into the 
effect of IOP fluctuation on glaucoma progression. Here 
we will review both the evidence and speculation on 
the effect of each kind of IOP fluctuation on glaucoma 
progression.
Instantaneous IOP Fluctuation
There is no direct evidence that instantaneous fluctuation 
has an effect on glaucoma progression. Animal 
experiments in primates have demonstrated brief 
high IOP spikes during saccades, blinks, and eye 
rubbing.[10,11] Other studies in animal models have shown 
that acute (though not necessarily instantaneous) IOP 
elevation can cause structural deformations of the optic 
nerve head or induce electrophysiologically measured 
functional changes.[12–15] Based on these animal studies, 
one may speculate that there are possible effects of 
transient, but high IOP peaks in susceptible eyes that 
undergo high strain associated with the stress of IOP 
spikes.
Diurnal-nocturnal IOP Fluctuation
There have been several reports on the effect of 
d iurnal ‑nocturnal  f luctuat ion  on  g laucoma 
progression.[16–19] Recently, De Moraes et al evaluated the 
relationship between a 24‑hour recording of IOP‑related 
measurements and the rate of visual field progression 
in treated glaucomatous eyes.[20] In this study, IOPs of 
forty treated glaucomatous patients were monitored 
with twenty‑four hour recordings using a contact lens 
sensor (CLS). They found that the number of large 
peaks (the number of peaks with a height of 90 mV or 
more) and the mean peak ratio (defined as the mean peak 
height to time‑to‑peak, which considers not only the 
magnitude of the peak, but also how fast it occurred) were 
the best predictors of faster glaucomatous progression. 
The results of this study suggest that a combination 
of CLS parameters obtained during a single 24‑hour 
session provides a signature that seems to explain the 
rate of glaucoma progression better than a summary of 
office‑hour IOP measurements over multiple visits.
Although it is well known that the highest IOP values 
usually occur at night, there may also be reasons why 
nocturnal changes of IOP may not affect the health of 
the optic nerve. Higher nocturnal IOP in humans is 
largely due to a supine sleeping position, and increased 
perfusion in the supine position may counteract IOP 
elevation. Increased cerebrospinal fluid (CSF) pressure in 
the supine position may also counteract the stress caused 
by IOP elevation by reducing the trans‑laminar pressure 
gradient. It is likely that other homeostatic mechanisms 
exist to compensate for regular biorhythms, such as those 
that occur with IOP and blood pressure.
Considering these possibilities, we may speculate 
that, although there is no evidence on the topic, diurnal 
or nocturnal IOP changes combined with alterations 
of systemic blood pressure and ocular blood flow may 
play a role in the pathogenesis of glaucoma. Thus, IOP 
fluctuations combined with an autoregulatory deficiency 
of ocular blood flow might damage tissues that are 
vulnerable to ocular perfusion pressure changes.[21]
Short-term IOP Fluctuation
Short‑term IOP fluctuation occurs over days to weeks. 
There is no evidence that short‑term fluctuation has 
a direct effect on glaucoma progression. However, 
this type of fluctuation may still be important, since 
short‑term fluctuation may predict long‑term fluctuation.
A study performed by Japanese researchers 
evaluated the relationship between short‑term IOP 
fluctuation (24‑hour fluctuation) measured by the 
Triggerfish® contact lens sensor (CLS; Sensimed AG, 
Lausanne, Switzerland) and long‑term IOP fluctuation 
measured during office visits over a mean follow‑up 
period of 5 years. They measured four parameters for 
determining long‑term IOP fluctuation:[22] 1) the mean 
IOP (mmHg) determined during follow‑up; 2) the IOP 
difference, which was defined as the difference between 
the maximum IOP and the minimum IOP; 3) the standard 
deviation of IOP; and 4) the peak IOP, which was defined 
as the maximum IOP. In this study, short‑term IOP 
fluctuation measured with the CLS was significantly 
correlated with long‑term IOP fluctuation [Figure 1]. The 
authors concluded that the examination of 24‑hour IOP 
fluctuation with the CLS might be useful for predicting 
long‑term IOP fluctuation.
Long-term IOP Fluctuation
Long‑term IOP fluctuation, which can be estimated from 
inter‑visit IOP measurements, was concluded to be a 
risk factor for glaucoma progression by a number of 
clinical trials. In the Advanced Glaucoma Intervention 
Study (AGIS), IOP fluctuation was an independent and 
stronger predictor than mean IOP for visual field (VF) 
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progression, and the association of IOP fluctuation 
with progression was the strongest in eyes with low 
mean IOPs.[23,24] According to a study published in 
2008, we found that the association of IOP fluctuation 
with progression was the strongest in eyes with low 
mean IOPs. In this AGIS subset population, there was a 
very weak correlation between the mean IOP and IOP 
fluctuation (R2 = 2.5%) [Figure 2]. When we categorized 
study participants according to their mean IOP values, 
IOP fluctuation was significantly associated with VF 
progression in the low mean IOP group (lower tercile 
group, mean IOP = 10.8 ± 2.5 mmHg), but not in the 
high mean IOP group (upper tercile group, mean 
IOP = 20.6 ± 4.5 mmHg, P = 0.2).
The Collaborative Initial Glaucoma Treatment 
Study (CIGTS) also showed that peak, SD, and range of 
IOP were all significant factors for 3 dB or more mean 
deviation (MD) loss, but that mean IOP failed to reveal a 
significant correlation with VF progression [Figure 3].[25,26]
Other evidence for the association between long‑term 
IOP fluctuation and VF progression is from the Japanese 
Archive of Multicentral Databases in Glaucoma (JAMDIG) 
study.[27] In this study, the mean total deviation (mTD) 
of the 52 test points in the 24‑2 HFA VF was calculated, 
and the relationship between mTD progression rate and 
seven clinical variables (age, mTD of baseline VF, 
average IOP, standard deviation (SD) of IOP, previous 
argon/selective laser trabeculoplasty (ALT/SLT), 
previous trabeculectomy, and previous trabeculectomy) 
was analyzed. There was no significant relationship 
between mean total deviation (mTD of VF) progression 
rate and mean IOP (P = 0.32, linear mixed model), 
whereas there was a significant relationship between the 
mTD progression rate and SD of IOP (P = 0.011, linear 
mixed model) [Figure 4].
Other reports have also implicated IOP fluctuation as 
an important risk factor in glaucoma progression.[28–31] A 
study by Hong et al addressed the question of long‑term 
IOP fluctuation.[29] In this study, a group of patients 
with IOPs consistently below 18 mmHg after a triple 
procedure (phacoemulsification, posterior chamber 
intraocular lens implantation, and trabeculectomy with 
mitomycin C) was evaluated for VF progression. Patients 
were divided into 2 groups: those with lower long‑term IOP 
fluctuation (SD ≤ 2 mmHg) and those with higher long‑term 
IOP fluctuation (SD > 2 mmHg). Though mean IOP and 
the number of glaucoma medications was equivalent in 
the 2 groups, the group with the lower IOP fluctuation 
demonstrated significantly better VF preservation.
However, not all studies have shown a positive 
association between disease progression and IOP 
fluctuation. Previous studies such as the Ocular 
Hypertension Treatment Study (OHTS), Early Manifest 
Glaucoma Treatment (EMGT), European Glaucoma 
Prevention Study (EGPS), Ocular Hypertension 
Treatment (OHT) in Diagnostic Innovations in Glaucoma 
Study (DIGS) found no influence of IOP fluctuation 
on VF progression.[32–35] The Early Manifest Glaucoma 
Treatment (EMGT) trial confirmed the strong effect 
of mean IOP on progression but found no evidence 
that IOP fluctuation was an independent risk factor 
for progression. Similarly, the OHTS did not report an 
independent relationship between IOP fluctuation and 
the development of glaucoma.
How can these different conclusions about the 
association of long‑term IOP fluctuation and glaucoma 
progression be explained? We need to consider the 
similarities of studies that failed to reveal significant 
correlations between IOP fluctuation and glaucoma 
progression. In those studies, participants had higher 
Figure 1. The correlation between short‑term (IOP fluctuation 
with CLS) and long‑term IOP fluctuation (standard deviation 
of IOP). The Spearman correlation coefficient was 0.3272, 
P = 0.0061. IOP: intraocular pressure; CLS: contact lens 
sensor. (From Tojo et al, Clin Ophthalmol 2016).
Figure  2 .  Scat tergram showing the  re lat ionship 
be tween  in t raocular  pressure  ( IOP)  f luc tuat ion 
(standard deviation of IOP measurements) and mean IOP. 
There was a weak but statistically significant correlation 
observed (Spearman r2 = 0.025, P = 0.006). Long‑term IOP 
fluctuation is associated with VF progression in patients with 
low mean IOP (area shaded in color), but not in patients with 
high mean IOP. IOP: intraocular pressure. (From Caprioli et al, 
Ophthalmology 2008).
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but stable IOPs, earlier glaucoma damage, and received 
relatively modest or no treatment compared to studies 
like AGIS or CIGTS. Treated patients in the EMGT 
had limited standardized treatment and did not have 
incisional surgery, and consequently had higher mean 
IOPs (16 mmHg). Treated OHTS patients had a mean 
IOP (19 mmHg) considerably higher than that in the 
AGIS (14‑15 mmHg, depending on race and treatment 
sequence, and 10.8 mmHg in the AGIS lower mean 
IOP tercile group) or than that in the study by Hong 
et al (10 mmHg). We hypothesize that greater IOP 
fluctuation is damaging in eyes with low mean IOPs 
(as in Hong et al, the AGIS, and the CIGTS), but when the 
mean IOP is higher, the role of IOP fluctuation becomes 
less important (as in the EMGT and the OHTS). Moreover, 
in the EMGT or OHTS, there existed strong correlations 
between the mean IOP and IOP fluctuation. Patients 
with the highest IOPs had the highest IOP fluctuation, 
whereas patients with low IOPs had the lowest IOP 
fluctuations. This correlation might mask the effect of 
IOP fluctuation on glaucoma progression. The AGIS 
population contained patients with moderate to advanced 
glaucomatous VF loss who had laser trabeculoplasty or 
trabeculectomy because maximal tolerated medical 
treatment failed to control their disease. Different studies 
have examined different groups of patients, at varying 
stages of disease, and at different mean IOP levels. 
Conclusions based on a single population may not be 
generalizable to other, more heterogeneous groups of 
patients. Considering these study population differences, 
we do not believe these findings to be contradictory, but 
rather complementary.
Why can IOP fluctuation be damaging? Physiologic 
IOP variation occurs in regular rhythmic cycles. Regular 
IOP peaks and valleys are normal, and compensatory 
mechanisms are in place to preserve the integrity of the 
tissue and the organism. If this “steady state” is disturbed 
by irregular elevations of IOP, or if normal compensatory 
mechanisms are faulty, damage may be more likely to 
occur. Long‑term variability may disrupt homeostatic 
mechanisms. Irregular and large IOP fluctuations may 
cause loading and unloading of stresses, and as opposed 
to conditions of static stress, the tissue is unable to 
compensate and damage occurs. It is also possible that 
periodic excursions into IOP levels that are damaging 
might occur, even though the IOP level measured during 
office visits seems nominal.
Relevance
In the clinical care of glaucoma patients, we should consider 
IOP “modulation” rather than simply IOP “reduction”. 
Quality‑based IOP control may be more important than 
quantity‑based IOP reduction to more effectively prevent 
disease progression. In cases of progressing primary open 
angle glaucoma (POAG) in clinical practice, not only a low 
IOP but also a constant (stable) IOP may be important 
to control the disease. Sustaining a constant IOP while 
reducing peaks may be as important as a low IOP in terms 
of disease progression, especially in patients who progress 
at low mean IOPs.
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